Equillium, Inc. (EQ) — SEC Financial Statements & Analysis

Equillium, Inc. (EQ) is a pharmaceutical preparations company, incorporated in DE. Equillium, Inc. trades on Nasdaq as: EQ. Equillium, Inc. (EQ)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Equillium, Inc. carries a market cap of $357.78M, a P/E ratio of -19.87x, a P/B ratio of 6.39x, a P/S ratio of 21.27x, an enterprise value of $300.61M, and an EV/EBITDA multiple of -15.66x. On profitability, it posts an operating margin of -554.92%, a net margin of -555.94%, a Return on Equity (ROE) of -58.98%, a Return on Assets (ROA) of -50.68%, and a Return on Invested Capital (ROIC) of -881.28%. Per share, it reports EPS of $-0.16, diluted EPS of $-0.16, free cash flow per share of $-0.18, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -10.82% year-over-year, and EPS growth of -71.51% year-over-year. On the balance sheet, it maintains a current ratio of 23.40x, a quick ratio of 23.07x, working capital of $55.50M, a debt-to-equity ratio of 0.05x, a debt ratio of 0.05, an interest coverage ratio of -19.78x, free cash flow of $-20.09M (TTM), and net debt of $-57.16M. Figures sourced from SEC EDGAR.

Market Cap

$357.78M

P/E TTM

-19.87x

EPS TTM

$-0.16

P/B TTM

6.39x

ROE TTM

-58.98%

ROA TTM

-50.68%

Debt To Equity

0.05x

Free Cash Flow TTM

$-20.09M

Net Revenue TTM Growth 1Y

-100.00%

Data as of 2026-06-30 · Source: SEC EDGAR